WTB
CLDX icon

Washington Trust Bank’s Celldex Therapeutics CLDX Stock Holding History

Washington Trust Bank’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-20
Closed -$5K – 772
2015
Q4 		$5K Hold
20
– – ﹤0.01% 649
2015
Q3 		$3K Hold
20
– – ﹤0.01% 711
2015
Q2 		$8K Hold
20
– – ﹤0.01% 687
2015
Q1 		$8K Buy
20
+3
+18% +$1.07K ﹤0.01% 696
2014
Q4 		$5K Hold
17
– – ﹤0.01% 773
2014
Q3 		$3K Buy
17
+10
+143% +$2.18K ﹤0.01% 763
2014
Q2 		$2K Hold
7
– – ﹤0.01% 827
2014
Q1 		$2K Buy
+7
New +$2.68K ﹤0.01% 787

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Washington Trust Bank's CLDX Position: Q1 2016 in Review

Washington Trust Bank sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 20 shares — an estimated $5K sold.

Washington Trust Bank first reported a position in CLDX in Q1 2014 and held it in 8 quarters. The position peaked at $8K in Q2 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • Washington Trust Bank reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Washington Trust Bank sold 20 Celldex Therapeutics shares in Q1 2016, an estimated $5K.
  • Washington Trust Bank first reported a position in Celldex Therapeutics in Q1 2014 and held it in 8 quarters.
  • Washington Trust Bank's Celldex Therapeutics position peaked at $8K in Q2 2015.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Washington Trust Bank's 13F filing for Q1 2016, filed 25 Apr 2016.